Company Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases.
The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.
Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers.
The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure.
The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021.
Renalytix Plc was incorporated in 2018 and is based in New York, New York.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 17, 2020 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 102 |
| CEO | James R. McCullough M.B.A. |
Contact Details
Address: Finsgate, 5-7 Cranwood Street London, X0 EC1V 9EE United Kingdom | |
| Phone | 44 29 2071 0570 |
| Website | renalytix.com |
Stock Details
| Ticker Symbol | RNLX |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $13.50 |
| CIK Code | 0001811115 |
| CUSIP Number | 75973T101 |
| ISIN Number | US75973T1016 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| James R. McCullough M.B.A. | Chief Executive Officer |
| Thomas H. McLain CPA, M.B.A | President |
| Oliver James Sterling III | Chief Financial Officer |
| Fergus Fleming | Chief Technology Officer |
| Dr. Michael J. Donovan M.D., Ph.D. | Chief Medical Officer |
| Howard B. Doran Jr. | Chief Business Officer |
| Salim Gulamabbas Hamir F.C.A. | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | 8-K | Current Report |
| Apr 23, 2024 | 8-K | Current Report |
| Apr 17, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 424B5 | Filing |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 29, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | 8-K | Current Report |